StockData

KALA BIO, Inc. (KALA) stock

KALANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026Score 5/30
$0.19+0.00 (+1.42%)

Close on Oct 19, 2026Market cap $14.28KP/E –Yield –

Kala Bio free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Kala Bio's free cash flow for the twelve months ending Sep 30, 2020 was -$84.63M. For fiscal 2019 it was -$94.06M. The highest annual figure on record is -$15.34M in fiscal 2015.

Annual free cash flow

PeriodPeriod endValueChange
FY2019Dec 31, 2019-$94.06M–
FY2018Dec 31, 2018-$55.70M–
FY2017Dec 31, 2017-$34.58M–
FY2016Dec 31, 2016-$27.50M–
FY2015Dec 31, 2015-$15.34M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2020Sep 30, 2020-$26.19M–
Q2 FY2020Jun 30, 2020-$19.88M–
Q1 FY2020Mar 31, 2020-$20.17M–
Q4 FY2019Dec 31, 2019-$18.40M–
Q3 FY2019Sep 30, 2019-$23.12M–
Q2 FY2019Jun 30, 2019-$20.93M–
Q1 FY2019Mar 31, 2019-$31.61M–
Q4 FY2018Dec 31, 2018-$16.90M–
Q3 FY2018Sep 30, 2018-$16.34M–
Q2 FY2018Jun 30, 2018-$9.37M–
Q1 FY2018Mar 31, 2018-$13.09M–
Q4 FY2017Dec 31, 2017-$6.85M–
Q3 FY2017Sep 30, 2017-$9.42M–
Q2 FY2017Jun 30, 2017-$8.88M–
Q1 FY2017Mar 31, 2017-$9.43M–
Q4 FY2016Dec 31, 2016-$7.39M–
Q3 FY2016Sep 30, 2016-$8.19M–

More Kala Bio figures

See a number that looks wrong?